Level of evidence for therapeutic drug monitoring for etoposide after oral administration

Fundamental and Clinical Pharmacology

Volumn 25, Issue 3, 2011, Pages 277-282

  Gerritsen van Schieveen, Pauline ^a   Royer, Bernard ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Etoposide; Level of evidence; Oral administration; Therapeutic drug monitoring

Indexed keywords

ETOPOSIDE;

ACUTE LYMPHOCYTIC LEUKEMIA; AREA UNDER THE CURVE; BAYESIAN LEARNING; BLOOD TOXICITY; BRONCHUS CANCER; CANCER PATIENT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BAYES THEOREM; BIOLOGICAL AVAILABILITY; DRUG MONITORING; ETOPOSIDE; HUMANS;

EID: 79954572275     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00856.x     Document Type: Review

References (19)

1. Toffoli G., Corona G., Basso B., Boiocchi M. Pharmacokinetic optimisation of treatment with oral etoposide. Clin. Pharmacokinet. (2004) 43 441-466.
2. Grunberg S.M., Crowley J., Hande K.R. et al. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother. Pharmacol. (1999) 44 461-468.
3. Perdaems N., Bachaud J.M., Rouzaud P. et al. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Eur. J. Clin. Pharmacol. (1998) 54 677-683.
4. Le Guellec C., Simon N., Hulot J.S., Billaud E.M., Marquet P., Groupe STP de la SFPT. Méthodologie pour l'évaluation du niveau de preuve du suivi thérapeutique pharmacologique. La lettre du pharmacologue (2009) 23 21-25.
5. Toffoli G., Corona G., Sorio R. et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br. J. Clin. Pharmacol. (2001) 52 511-519.
6. Ando M., Minami H., Ando Y. et al. Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin. Cancer Res. (1999) 5 1690-1695.
7. Yong W.P., Desai A.A., Innocenti F. et al. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother. Pharmacol. (2007) 60 811-819.
8. Gregianin L.J., Brunetto A.L., Di Leone L., Costa T.D., Santos P.P., Schwartsmann G. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies. Med. Sci. Monit. (2002) 8 PI70-PI77.
9. Edick M.J., Gajjar A., Mahmoud H.H. et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. (2003) 21 1340-1346.
10. el-Yazigi A., Ezzat A., Berry J. et al. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. J. Clin. Pharmacol. (2000) 40 153-160.
11. Miller A.A., Tolley E.A., Niell H.B. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Clin. Cancer Res. (1998) 4 1705-1710.
12. Ratain M.J., Schilsky R.L., Choi K.E. et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin. Pharmacol. Ther. (1989) 45 226-233.
13. Joel S.P., Ellis P., O'Byrne K. et al. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J. Clin. Oncol. (1996) 14 1903-1912.
14. Joel S., O'Byrne K., Penson R. et al. A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann. Oncol. (1998) 9 1205-1211.
15. Hande K., Messenger M., Wagner J., Krozely M., Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin. Cancer Res. (1999) 5 2742-2747.
16. Aita P., Robieux I., Sorio R. et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother. Pharmacol. (1999) 43 287-294.
17. Freyer G., Tranchand B., Ligneau B. et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br. J. Clin. Pharmacol. (2000) 50 315-324.
18. Nguyen L., Chatelut E., Chevreau C. et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother. Pharmacol. (1998) 41 125-132.
19. Kloft C., Wallin J., Henningsson A., Chatelut E., Karlsson M.O. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin. Cancer Res. (2006) 12 5481-5490.